Close Menu

lymphoid cancer

The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.

An exome- and expression-based analysis of 304 DLBCL cases led to five molecular subtypes, offering insights into disease pathogenesis and treatment outcomes.

NEW YORK (GenomeWeb News) – Investigators at the BC Cancer Agency in British Columbia have reeled in an infusion of C$10 million (US$9.5 million) in funding from regional and national partners to fund an effort to use genome sequencing to personalize treatments for patients with lymphoid cancers.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.